Molecular Devices Corp.
This article was originally published in The Gray Sheet
Executive SummarySecondary offering of $150 mil. in common stock is outlined in a filing with the Securities and Exchange Commission, including shares to be offered by the company and selling shareholders. Underwriters for the offering include ING Barings, Bear Stearns, Thomas Weisel Partners and Warburg Dillon Read. The Sunnyvale, California firm launched two high throughput microplate readers for use in drug discovery and life science research March 6, including the Spectramax Gemini XS fluorescence microplate reader and Plus384 absorbance microplate reader
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.